DE69728783T2 - Verbesserte arzneimittel - Google Patents

Verbesserte arzneimittel Download PDF

Info

Publication number
DE69728783T2
DE69728783T2 DE69728783T DE69728783T DE69728783T2 DE 69728783 T2 DE69728783 T2 DE 69728783T2 DE 69728783 T DE69728783 T DE 69728783T DE 69728783 T DE69728783 T DE 69728783T DE 69728783 T2 DE69728783 T2 DE 69728783T2
Authority
DE
Germany
Prior art keywords
oil
water
suspension
formulation
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69728783T
Other languages
German (de)
English (en)
Other versions
DE69728783D1 (de
Inventor
P. Todd FOSTER
L. David KIEFER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69728783(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of DE69728783D1 publication Critical patent/DE69728783D1/de
Application granted granted Critical
Publication of DE69728783T2 publication Critical patent/DE69728783T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69728783T 1996-12-09 1997-12-03 Verbesserte arzneimittel Revoked DE69728783T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions
US806584 1996-12-09
PCT/US1997/021401 WO1998025621A1 (en) 1996-12-09 1997-12-03 Improved pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69728783D1 DE69728783D1 (de) 2004-05-27
DE69728783T2 true DE69728783T2 (de) 2005-03-31

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69728783T Revoked DE69728783T2 (de) 1996-12-09 1997-12-03 Verbesserte arzneimittel

Country Status (21)

Country Link
US (1) US5736151A (enExample)
EP (1) EP0941095B1 (enExample)
JP (1) JP2001505910A (enExample)
KR (1) KR100544248B1 (enExample)
CN (1) CN100413506C (enExample)
AT (1) ATE264681T1 (enExample)
AU (1) AU746666B2 (enExample)
BR (1) BR9714967B1 (enExample)
CA (1) CA2269682C (enExample)
CZ (1) CZ297632B6 (enExample)
DE (1) DE69728783T2 (enExample)
DK (1) DK0941095T3 (enExample)
ES (1) ES2218705T3 (enExample)
FI (1) FI991302L (enExample)
HU (1) HUP0000564A3 (enExample)
NO (1) NO325475B1 (enExample)
NZ (1) NZ336183A (enExample)
PL (1) PL190662B1 (enExample)
PT (1) PT941095E (enExample)
SK (1) SK72399A3 (enExample)
WO (1) WO1998025621A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136367D1 (de) * 2000-09-12 2008-12-11 Pharmacia & Upjohn Co Llc Pharmazeutische zusammensetzung mit modifiziertem träger
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
EP1528926A1 (en) * 2002-08-07 2005-05-11 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
DE602004002201T2 (de) * 2003-03-20 2007-09-20 Pharmacia Corp. Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
CA2529405A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
BRPI0922041A8 (pt) * 2008-11-19 2022-08-16 Merial Ltd Formulações compreendendo ceftiofur e cetoprofeno ou cetiofur e álcool benzílico.
EP2874624B8 (en) 2012-07-17 2019-10-02 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2018071810A1 (en) 2016-10-13 2018-04-19 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
NL120012C (enExample) * 1961-01-31
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
US4937330A (en) * 1985-08-12 1990-06-26 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
EP0393066B1 (en) * 1987-11-10 1994-02-02 The Upjohn Company Cephalosporin antibiotics
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
AU639004B2 (en) * 1989-06-13 1993-07-15 Abbott Laboratories Anhydrous oil-based liquid suspension for delivering a medicament
CZ289332B6 (cs) * 1993-03-12 2002-01-16 Pharmacia & Upjohn Company Krystalická volná kyselina ceftiofuru, způsob její přípravy a farmaceutický prostředek s jejím obsahem

Also Published As

Publication number Publication date
NO992780D0 (no) 1999-06-08
FI991302A0 (fi) 1999-06-08
CN1238690A (zh) 1999-12-15
KR100544248B1 (ko) 2006-01-23
US5736151A (en) 1998-04-07
CA2269682C (en) 2009-04-14
JP2001505910A (ja) 2001-05-08
BR9714967B1 (pt) 2010-06-29
WO1998025621A1 (en) 1998-06-18
ATE264681T1 (de) 2004-05-15
CA2269682A1 (en) 1998-06-18
DE69728783D1 (de) 2004-05-27
CZ297632B6 (cs) 2007-02-14
EP0941095A1 (en) 1999-09-15
AU5452998A (en) 1998-07-03
NZ336183A (en) 2000-12-22
SK72399A3 (en) 2000-05-16
NO992780L (no) 1999-06-08
NO325475B1 (no) 2008-05-13
HUP0000564A2 (hu) 2000-10-28
HK1023292A1 (zh) 2000-09-08
KR20000069360A (ko) 2000-11-25
PL190662B1 (pl) 2005-12-30
CN100413506C (zh) 2008-08-27
ES2218705T3 (es) 2004-11-16
PT941095E (pt) 2004-08-31
FI991302A7 (fi) 1999-06-08
HUP0000564A3 (en) 2001-01-29
FI991302L (fi) 1999-06-08
EP0941095B1 (en) 2004-04-21
DK0941095T3 (da) 2004-08-02
AU746666B2 (en) 2002-05-02
BR9714967A (pt) 2001-10-30
CZ202599A3 (cs) 1999-09-15

Similar Documents

Publication Publication Date Title
DE69728783T2 (de) Verbesserte arzneimittel
DE3240177C2 (enExample)
DE69018647T2 (de) Arzneimittel.
DE69917883T2 (de) Phospholipid-beschichtete Mikrokristalle für die länger anhaltende Freisetzung von pharmakologisch aktiven Verbindungen und Verfahren zu deren Herstellung und deren Verwendung
DE60132108T2 (de) Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion
DE69621942T2 (de) Verbessertes herstellungsverfahren und zusammensetzung für therapeutisches cisplatin (cddp)
DE60204897T2 (de) Kristalline freie base von clindamycin
CH639845A5 (en) Solid depot pharmaceutical preparations and process for their production
DE3215844A1 (de) Mischsalz aus glucosaminsulfat und natriumchlorid
DE68903814T2 (de) Etoposid-loesungen.
DE3782117T2 (de) Verkapselung von trh bzw. dessen analoga.
DE2512391C2 (de) Mittel zur Behandlung der Mastitis in Milchtieren
EP1750700B1 (de) Flüssige zubereitung für die veterinärmedizin; verfahren zu deren herstellung und deren verwendung
DE3536560A1 (de) Augentropfen enthaltend bromokryptin
DE69928500T2 (de) Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat
DE68922127T2 (de) Zinkceftiofurkomplexe.
AT397460B (de) Verfahren zur herstellung eines pharmazeutischen trockenpräparates enthaltend ein diclofenac-salz
DE69004921T2 (de) Injizierbare Cephalosporinpräparate und ihre Anwendung.
DE2506622C2 (de) Antibiotisch wirksames Arzneimittel
DE69003174T2 (de) Etoposid-Präparate.
DE68912270T2 (de) Lyophilisiertes MDM enthaltende Zusammensetzung und Verfahren zu deren Herstellung.
DE2718730A1 (de) Cephalosporin-antibiotika
CH647677A5 (de) 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung.
DE69232409T2 (de) Ungepufferte, vorgemischte ranitidin-formulierung
DE19912436A1 (de) Ibuprofen-Lösung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation